Hi @dachopper,
We’ve been told the protocol for the adult trial’s been submitted. No reason I can think of that it wouldn’t have been sought to be designed by BMT CTN to be both confirmatory to FDA’s expectations & able to support label extension to adults. But I’m chewing on @Stellowe’s good points re endpoints.
So are you thinking AA for the paediatric indication & not standard approval then?
Cheers
2024 Here we go again., page-459
-
- There are more pages in this discussion • 485 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.025(2.36%) |
Mkt cap ! $1.218B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.09 | $1.06 | $1.426M | 1.326M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 39397 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 208287 | 10 |
View Market Depth
| Last trade - 12.51pm 03/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |